ArticleFrontiers in endocrinology2025
TyG index and MAFLD severity are associated with subclinical LV dysfunction in T2DM patients: a cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study.Frontiers in endocrinology · 2026Article
- Associations of the triglyceride-glucose index and its composite indices with mortality in adults with T2DM.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent in type 2 diabetes mellitus (T2DM) and may contribute to early myocardial dysfunction. The Fibrosis-4 (Fib-4) index is a reliable marker of hepatic fibrosis, and the triglyceride-glucose (TyG) index is an effective indicator of insulin resistance (IR). Both are linked to various cardiovascular diseases (CVDs).However, their combined impact on subclinical left ventricular dysfunction (SLVD) remains unclear. This study aimed to explore the associations between hepatic fibrosis, IR, and SLVD in T2DM patients. Methods: We enrolled 270 T2DM patients between September 2024 and April 2025.MAFLD was diagnosed by ultrasonography, hepatic fibrosis was assessed using the Fib-4 index, and insulin resistance was estimated using the TyG index formula. Left Ventricular Global Longitudinal Strain (LV GLS) was measured by speckle-tracking echocardiography, with SLVD defined as absolute value of LV GLS <18%. T2DM patients were divided into three groups based on the presence of MAFLD and Fib-4 <1.3 or ≥1.3: non-MAFLD, MAFLD+Fib-4<1.3, and MAFLD+Fib-4≥1.3, and further stratified by the TyG median. Multivariable logistic regression models were used to evaluate the independent and interactive associations of Fib-4 index and TyG index with SLVD. Results: Compared to non-MAFLD patients, T2DM patients with MAFLD were younger, had a shorter duration of diabetes, and exhibited worsened lipid profile, with higher TyG values and lower LV GLS. MAFLD independently predicted SLVD (adjusted OR = 3.21, 95% CI: 1.64-6.29). Even in patients with Fib-4 <1.3, MAFLD was associated with higher SLVD risk (OR = 2.94), while advanced fibrosis further increased SLVD risk (OR = 3.68). TyG independently predicted SLVD (adjusted OR = 2.73, 95% CI: 1.48-5.03). Importantly, patients with both high Fib-4 (≥1.3) and high TyG (≥9.03) had the greatest SLVD risk (OR = 7.58), whereas advanced fibrosis alone was not significant. Conclusions: Fib-4 index and TyG index are independent predictors of SLVD in T2DM, and their coexistence exerts a synergistic effect. Combined assessment provides a simple, non-invasive tool for early risk stratification, highlighting the clinical importance of the liver-heart axis in identifying SLVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.